CompletedPhase 4

Effect of Schistosomiasis Mansoni on HIV Susceptibility and Female Genital Immunology

Uganda34 participantsStarted 2016-03

Plain-language summary

The aim of this study is to assess the impact of Schistosoma mansoni infection and its treatment on genital immunology and HIV susceptibility in Ugandan women.

Who can participate

Age range18 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Positive (score above "trace") on a urine CCA rapid test * Willing to be treated with praziquantel * Willing to give informed consent, and answer short questionnaires on economic status, and sexual risk behavior. * Willing to comply with the requirements of the protocol * HIV and classical STI (see below) negative Exclusion Criteria: * HIV infected * Malaria infected * Pregnant. * Irregular menstrual cycle, or actively menstruating at the time of genital sampling. * Tested positive for classical STIs (syphilis, gonorrhea, chlamydia, Trichomonas vaginalis) or having genital ulcers * Prior hysterectomy * Deemed by physician to be unlikely to complete study protocol.

What they're measuring

Change in the percentage of endocervical CD4+ T cells susceptible to HIV pseudovirus entry after treatment of schistosomiasis.

Timeframe: 1 month.

Change in the number of endocervical CD4+ T cells susceptible to HIV pseudovirus entry after treatment of schistosomiasis.

Timeframe: 1 month.

Trial details

NCT IDNCT02878564

SponsorUniversity of Toronto

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-10

View on ClinicalTrials.gov More Schistosomiasis Mansoni trials